postbiotic

Industry, Oncology

Microbio’s MS-20 shows breakthrough potential in enhancing Keytruda for advanced lung cancer

The study revealed that MS-20 dramatically improved treatment outcomes, tripling the objective response rate (ORR) to 75% when combined with Keytruda.

Industry

Adare Pharma Solutions announces divestiture of postbiotics pioneer Adare Biome to dsm-firmenich

The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

MicrobiomePost

MicrobiomeHUB

Via Podgora 12/A, 20122, Milan, Italy – VAT: IT05299040963

Read MicrobiomePost’s Privacy Policy

This communication is only intended for business-to-business and health care professionals.
This communication is not intended for consumers of final consumer goods.
Nothing on this page is meant to be perceived as an approved claim.